The cancer vaccine gold rush has begun, with companies racing to capitalize on personalized therapies. Tempus AI is positioned to capture a lucrative slice of Moderna and Merck’s personalized cancer therapy business. At the center of this bet is Personalis, which provides critical genomic sequencing and data analysis tools essential for developing individualized cancer vaccines.

As Moderna and Merck advance their cancer vaccine candidates, the demand for precision diagnostics and bioinformatics infrastructure is surging. Tempus AI’s platform, which integrates clinical and molecular data, enables the identification of neoantigens unique to each patient’s tumor— a key step in personalized vaccine development. Personalis, meanwhile, specializes in high-resolution tumor and immune profiling, making it a foundational supplier in the ecosystem.

Together, these companies form a critical supply chain for the next generation of cancer immunotherapies. Investors are increasingly viewing diagnostics and data firms as the “picks and shovels” of this emerging market, analogous to the infrastructure plays during past technological booms. The convergence of AI, genomics, and immunotherapy is accelerating innovation, with Tempus AI and Personalis poised to benefit from long-term contracts and licensing deals as cancer vaccines move toward commercialization.